Kornimate/medical-research-clean huggingface dataset:
early glue saphenous vein ablation with compression versus compression alone in the healing of the venous ulcer

Conditions: Venous Leg Ulcer

Summary: the study evaluates the effects of early endovenous glue ablation on ulcer healing in patients with chronic venous ulceration. half the patients are randomized to receive early endovenous ablation (within 2 weeks) and a half to standard care

to get the venous leg ulcer to heal, the current best treatment is to wear a multi-component compression bandage, with which about 60% of these ulcers will heal within 24 weeks. there is evidence that treatment of the varicose veins by surgery will prevent the ulcer from returning after it has healed. recent studies have suggested that newer techniques of treating varicose veins, such as sclerotherapy, laser or radiofrequency in an outpatient setting may help the ulcers to heal more quickly and reduce the chance of the ulcer recurrence. the aim of this study is to see whether early treatment of varicose veins using endovenous glue embolization helps with healing.

Eligibility criteria:
inclusion criteria: * current leg ulceration of greater than 6 weeks, but less than 6 months duration * able to give informed consent to participate in the study after reading the patient information documentation * patient age \> 18 years * ankle brachial pressure index (abpi) ≥ 0.8 * superficial venous disease on colour duplex assessment deemed to be significant enough to warrant ablation by the treating clinician (either primary or recurrent venous reflux) exclusion criteria: * presence of deep venous occlusive disease or other conditions precluding superficial venous intervention * patients who are unable to tolerate any multilayer compression bandaging / stockings will be excluded. * the inability of the patient to receive the prompt endovenous intervention * pregnancy (female participants of reproductive age will be eligible for inclusion in the study, subject to a negative pregnancy test prior to randomisation)

Keywords: venous leg ulcer glue embolization saphenous vein reflux
ketamine versus dexmedetomidine for prevention of postoperative delirium

Conditions: Emergence Delirium

Summary: delirium is a common postoperative complication in the elderly, often caused by multiple factors. it is defined as an acute neuropsychiatric disorder characterized by fluctuating disturbances in attention, awareness, and cognition. postoperative delirium occurs in 17-61% of the major surgical procedures. it may be associated with cognitive decline, decreased functional independence, increased risk of dementia, caregiver burden, health care costs, morbidity, and mortality. therefore, delirium is a possibly disastrous condition and is both a huge burden on a patient's health and on the health care system in general.

over the last few decades, numerous risk factors for delirium have been identified, emphasizing the importance of delirium prevention in patients undergoing surgery. it has already been identified as a state that may be associated with serious complications such as prolonged icu and hospital stays, decreased quality of life, and increased mortality ). previous studies on delirium pointed out old age and other factors as important predisposing factors. on the health care system in general. extensive research on reducing the incidence of delirium has been conducted using both pharmacological and non-pharmacological preventive measures in the acute setting. as evidence recommending or opposing specific drugs for the prevention of postoperative delirium remains insufficient and the international guidelines can only recommend perioperative pharmacologic adjustments ("american geriatrics society abstracted clinical practice guideline for postoperative delirium in older adults," 2015) . consequently, the challenge of developing reliable hospital algorithms for delirium prevention and treatment remains unresolved. furthermore, there is a link between postoperative delirium and two biomarkers, cortisol and c- reactive protein (crp), which have previously been linked to delirium but whose significance is unknown.

Eligibility criteria:
inclusion criteria: * 1- patients aged ≥ 65 years. 2- scheduled for visceral, orthopedic, vascular, obstetric, urology, or plastic surgery. exclusion criteria: * 1- delirium upon hospital admission or development of delirium prior to surgery stated by family members. 2- mini-mental state examination (mmse) score \< 24 points 3- delirium observation scale (dos) ≥4 points 4- preoperative neurological diseases affecting cognitive function (such as vascular dementia) 5- high risk for postoperative treatment in the intensive care unit (icu) 6- known to have dexmedetomidine and or ketamine intolerance. 7- lack of cooperation or communication. 8- parkinson's disease, parkinsonism, intake of dopaminergic drugs (levodopa, dopamine agonists) 9- epilepsy. 10- patients on steroid therapy 11- severe liver and renal insufficiency
pharmacodynamic study of azd1722 in end-stage renal disease patients on hemodialysis

Conditions: End Stage Renal Disease; Chronic Kidney Disease Stage 5; ESRD

Summary: the purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with end stage renal disease on hemodialysis.

this is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of the study drug in male and female patients with end-stage renal disease on hemodialysis. the study consists of a 2 week treatment-free run-in period where entry criteria are verified, a 4-week treatment period, of which the first week of treatment will be performed as an in-patient study in a clinical pharmacology unit (cpu) and the remaining three weeks of treatment will performed as an out-patient study, and a 2-week treatment-free follow-up period. safety assessments will be performed at regular intervals and will include clinical and vital signs, clinical laboratory evaluations, ecgs, and ae monitoring. pharmacodynamic assessments will include, but are not limited to, interdialytic weight gain (idwg), blood pressure, and stool sodium excretion. pharmacokinetic assessments will include blood sampling for measurement of study drug plasma concentrations.

Eligibility criteria:
inclusion criteria: * males or females aged 18 to 80 years, inclusive; * body mass index between 18 and 45 kg/m2, inclusive; * ambulatory (≥ 6 months) maintenance hemodialysis; * stable dialysis treatment regimen 3x/week for ≥ 2 months prior to screening visit. exclusion criteria: * currently taking diuretic medication; * has a urine production of ≥ 200 ml/day (based on a 24-hour measurement starting on day -1 and completed prior to randomization); * predialysis systolic bp \>200 mmhg or diastolic bp \>110 mmhg on two successive occasions during the 2-week run-in period; * predialysis sbp \< 110 mmhg on two successive occasions during the 2-week run-in period

Keywords: hemodialysis
interaction study in patients with pulmonary hypertension and stable treatment of sildenafil 20 mg tid

Conditions: Hypertension, Pulmonary

Summary: this study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of bay63-2521 in patients with pulmonary hypertension and stable treatment of sildenafil 20 mg.


Eligibility criteria:
inclusion criteria: * patients with pulmonary hypertension stable for the last 6 weeks * treated with sildenafil 3 × 20 mg * undergoing routine invasive diagnostics. exclusion criteria: * pre-existing lung disease other than pulmonary arterial hypertension, * acute or severe chronic left heart failure, * severe coronary artery disease, * uncontrolled arterial hypertension; * congenital or acquired valvular or myocardial disease except acquired tricuspid valve insufficiency due to pulmonary hypertension, * systolic blood pressure \ 105 bpm, pao2/fio2 \< 50 mmhg, * paco2 \> 55 mmhg, * severe hepatic insufficiency, * severe renal insufficiency, * administration of strong cyp3a4 inhibitors or inductors

Keywords: pulmonary hypertension
translation and clinical implementation of a test of language and short-term memory in aphasia

Conditions: Aphasia

Summary: this project aims to develop a clinically feasible version of a laboratory-developed assessment battery for language and verbal short-term memory difficulties in aphasia.

over five years, we will develop a clinically feasible test that can be used to assess in-depth the language and verbal short-term memory abilities of individuals with aphasia (called the talsa - temple assessment of language and short-term memory in aphasia. based on a test that we have developed and tested over the past decade, we will create a shorter version that can be used by clinicians in a rehabilitation setting. the data to support this development will come from two sources: (1) clinicians in rehabilitation facilities who will use the new clinical test and provide feedback on the test (administration, value etc) and (2) people with aphasia who will be administered the longer version to help us identify the best test items in the laboratory version of the talsa to be carried over to the shorter clinical version. we are recruiting individuals with aphasia as well as people without aphasia (to serve as controls) to help with development of this assessment battery. the battery consists of between 15 and 20 subtests that assess many aspects of language and verbal short-term memory.

Eligibility criteria:
inclusion criteria: * . single or multiple left hemisphere lesions * at least one year post-stroke. * high-school educated * negative histories for mental illness and alcohol/substance abuse. * passed an audiometric pure-tone, air conduction screening at 25 db hl at 1k, 2k and 4k hz for at least one ear. exclusion criteria: english as a second language right hemisphere stroke less than 6 months post-onset of stroke.

Keywords: aphasia
family & friends - the significance of a significant other in treatment

Conditions: Obesity

Summary: this study focuses on the difficulties to maintain a weight loss and behavioural change after having been in a institutional intermittent weight loss programme. we explore if including a member of the family or a close friend in the treatment influences weight loss maintenance after completion of the programme.


Eligibility criteria:
inclusion criteria: * morbid obesity * 18-50 years of age * having a relative or close friend who is willing to participate exclusion criteria: * pregnancy * serious mental illness * severe overeating behaviour * significant reduced physical functioning * having undergone bariatric surgery earlier * serious heart disease

Keywords: weight loss social support
vf test for prediction of extremely ptb after cerclage

Conditions: Preterm Birth; Infection

Summary: the purpose of this research study is to determine if a vaginal fluid (vf) test can predict very early preterm birth in patients who are scheduled to have an exam indicated cerclage for severe cervical shortening. prior to participants undergoing a scheduled amniocentesis two swabs to collect vaginal secretions for the vf tests will be done. during the amniocentesis your doctor will remove amniotic fluid as part of the routine clinical care. from that fluid sample, the study will use less than a quarter teaspoon for the amniotic fluid study test (af test). data regarding maternal and birth outcomes will be collected by medical record review.

the purpose of this research study is to determine if a vaginal fluid (vf) test can predict very early preterm birth in patients who are scheduled to have an exam indicated cerclage for severe cervical shortening. prior to participants undergoing a scheduled amniocentesis, an ultrasound will be done to confirm cervical length and dilation. during a separate sterile speculum exam, the physician will use two swabs to collect vaginal secretions for the vf test. during the amniocentesis the doctor will remove approximately 2 teaspoon of amniotic fluid as part of your standard clinical care. from that fluid sample, the study will use less than a quarter teaspoon for a amniotic fluid study test (af test). data regarding maternal and birth outcomes will be collected by medical record review. the vaginal fluid (vf) sample collection will take approximately 15 minutes to do. the total time in the study is about seven and a half months (from the time the patient consents until 4 weeks after delivery). the only study procedure the patient will experience during her study participation is the collection of the vaginal fluid specimens.

Eligibility criteria:
inclusion criteria: * participant age 18 years or older * gestational age between 16w0d to 25w6d * singleton fetus with no apparent major anomalies on ultrasound exam * sonographically absent cervical length and/or sterile digital exam of 2cm or greater dilation * exam-indicated cervical cerclage has been recommended by clinician and patient agrees to proceed with cervical cerclage placement * decision has been made by provider to perform pre-cerclage amniocentesis to rule-out infection, with the understanding that cerclage is contraindicated if findings indicate probable or definitive infection, and patient agrees. exclusion criteria: * planned termination of pregnancy * clinical features consistent with placental abruption or chorioamnionitis * need for immediate delivery based on maternal or fetal issues * fetus with ultrasound-determined major congenital anomalies * multiple gestation * rupture of membranes * patient does not give consent to participate in this study

Keywords: cerclage preterm birth
efficacy of olanzapine on weight gain in advanced gynecologic cancer with paclitaxel and carboplatin: a double blind, placebo-controlled randomized trial

Conditions: Weight Gain

Summary: * efficacy of olanzapine on weight gain in advanced stage gynecologic cancer * proprotion of pateints in advanced stage gynecologic cancer who recieving paclitaxel and carboplatin chemotherapy gain weight on olanzapine or placebo

-proprotion of pateints in advanced stage gynecologic cancer who recieving paclitaxel and carboplatin chemotherapy gain weight on olanzapine or placebo

Eligibility criteria:
inclusion criteria: * advanced stage gynecologic cancer receiving paclitaxel and carboplatin chemotherapy * ecog 0-1 * normal cbc,liver, renal function * communication in thai language or thai caregiver * inform consent exclusion criteria: * pregnancy * active infection * bowel obstruction or history of bowel surgery * on dopamine receptor antagonists or psychiatric or anticonvulsant medication * olanzapine allery * abnormal function of liver and renal * diabetic melitus or morbid obesity * patient can't selfcare
dopamine d2 receptors(d2r) imaging in prolactinomas

Conditions: Prolactinoma

Summary: to study the in vivo expression of dopamine d2 receptors in prolactinoma and the predictive role of dopamine d2 receptors pet-mr imaging in the therapeutic effect of dopamine agonists.

the dopamine agonist(da),such as cabergoline(cab) and bromocriptine(bc), has been used widely in the treatment of prolactinomas, but its clinical use is hampered by intolerance and/or resistant in some patients. it had been showed that da inhibit prolactin secretion by binding to and activating dopamine d2 receptors.pet-mr combined mr images with pet function images is substantial to evaluate the expression of dopamine d2 receptors.the aim is to study the in vivo expression of dopamine d2 receptors in prolactinoma and the predictive role of dopamine d2 receptors pet-mr imaging in the therapeutic effect of da.

Eligibility criteria:
inclusion criteria: 1. hyperprolactinemia; 2. enhanced pituitary mri shows sella regional tumor; 3. aged between 18 and 65 years old, either sex; 4. karnofsky performance status ≥ 70; 5. the patient has signed the informed consent. exclusion criteria: 1. patients concomitantly taking the psychotropic drugs or other drugs causing elevated prl ; 2. patients with parkinson disease and is taking dopaminergic agents; 3. patients with prolactinoma who received gamma knife treatment; 4. pregnant or lactating women, or women preparing pregnant; 5. patients with poor compliance, who cannot implement the program strictly. 6. history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline. 7. patients with claustrophobia

Keywords: dopamine agonist dopamine d2 receptors pet-mr
clinical trial to evaluate the safety and efficacy of jp-1366 in patients with erosive gastroesophageal reflux disease

Conditions: GERD

Summary: clinical trial to evaluate the safety and efficacy of jp-1366 in patients with erosive gastroesophageal reflux disease


Eligibility criteria:
inclusion criteria: * adults between 19 and 75 years old based on the date of written agreement * those who have been diagnosed with erosive gastroesophageal reflux disease(egrd) of la grade a-d on the upper gastrointestinal endoscopy * those who experienced symptoms of heartburn or acid reflux within the last 7 days exclusion criteria: * those who have undergone gastric acid suppression or gastric, esophageal surgery * those who with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease * clinically significant abnormal laboratory values during screening
extension to a study on the efficacy and safety of vildagliptin in combination with pioglitazone in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. this is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to pioglitazone in people with type 2 diabetes not at target blood glucose levels on pioglitazone or rosiglitazone alone. the purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * only patients successfully completing study claf237a2304 are eligible * written informed consent * ability to comply with all study requirements exclusion criteria: * premature discontinuation from study claf237a2304 * other protocol-defined exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin
ctdna analysis to monitor the risk of progression after first-line immunotherapy in patients with advanced nsclc

Conditions: Advanced Lung Non-Small Cell Carcinoma

Summary: this study aims to explore the correlation of circulating tumor dna(ctdna) and the risk of progression in patients with advanced nsclc who have long-term benefit from first-line immunotherapy (pfs 12 months)

evidence suggests that circulating tumor dna (ctdna) analysis can noninvasively identify minimal residual disease (mrd) in clinical oncology. the researches will be sharply increased about ctdna potential clinical application in the near future. in the early stage of nsclc, ctdna has been indicated to identify those at high risk of recurrence after radical surgery. and this study will focus on those patients with advanced nsclc who have long-term benefit from first-line immunotherapy (pfs 12 months). 10ml plasma will be collected every three months until disease progression to interrogate ctdna by high-depth panel sequencing, exploring its prediction value about the risk of progression. meanwhile, the investigators would like to explore the lead time of detectable ctdna before regular imaging finding.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * advanced non-small cell lung cancer (stage iiib-iv), pathological types limited to squamous cell carcinoma or non-squamous cell carcinoma, driver gene mutations (egfr/alk/ros1) were negative * general condition: ecog score 0 or 1 * first-line monotherapy or combination immunotherapy * the long-term benefit of immunotherapy was defined as pfs=12months * tumor tissue samples can be obtained at the time of enrollment, and at least 5 \~ 10 sections can be generated, and the pathological report indicates that the overall tumor content is not less than 10% or ngs testing with a fixed-panel is available; or no tumor tissue is available. * at least one measurable lesion (except patients with cr after first-line treatment) can be evaluated according to recist1.1 standard. * have self-awareness, be able to understand the research scheme and voluntarily participate in the study, and can sign the informed consent form * have good compliance, be able to cooperate with the collection of specimens from each node and provide corresponding clinical information. exclusion criteria: * serious primary diseases of the heart, liver and kidney * other malignant tumors within 3 years prior to diagnosis of nsclc * women in pregnancy and lactation * the active stage of human immunodeficiency virus (hiv) infection * patients with active systemic infection, pneumonia, tuberculosis, pericarditis * patients who cannot understand the content of the experiment and cannot cooperate and refuse to sign informed consent.

Keywords: ctdna advanced lung cancer first-line immunotherapy the risk of progression minimal residual disease (mrd) long-term benefit